HUA Hui,LIU Cong,HE Yu-xia,et al.Mechanism of Xueniao Capsule in Treatment of Acute Pyelonephritis Based on Network Pharmacology[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(02):208-219.
HUA Hui,LIU Cong,HE Yu-xia,et al.Mechanism of Xueniao Capsule in Treatment of Acute Pyelonephritis Based on Network Pharmacology[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(02):208-219. DOI: 10.13422/j.cnki.syfjx.20220113.
Mechanism of Xueniao Capsule in Treatment of Acute Pyelonephritis Based on Network Pharmacology
To explore the mechanism of Xueniao capsule in the treatment of acute pyelonephritis (APN) by network pharmacology and experimental verification.
Method
2
The effect of Xueniao capsule on APN was investigated based on the APN model in rats. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Chemistryl Database, and SymMap were searched for the chemical components of Smilacis Chinae Rhizoma,Coicis Semen, and Trachycarpi Petiolus. The target information of the components was collected from PharmMapper and SwissTargetPrediction, and disease target information from Therapeutic Target Database (TTD), DrugBank, DisGeNET, GeneCards, and Online Mendelian Inheritance in Man(OMIM). The key genes of Xueniao capsule for APN underwent Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analyses by Metascap. Real-time quantitative polymerase chain reaction (PCR) and Western blot were employed to verify the prediction results.
Result
2
Compared with the blank group and the sham operation group, the model group showed an increased ratio of the left kidney to the right kidney and organ index(
P
<
0.05,
P
<
0.01),up-regulated white blood cells (WBC),neutrophils (NEUT),monocytes (MONO), and lymphocytes (LY)(
P
<
0.05,
P
<
0.01), and elevated levels of nuclear factor-
κ
B(NF-
κ
B), interleukin-6 (IL-6), and tumor necrosis factor-
α
(TNF-
α
)(
P
<
0.05,
P
<
0.01). Compared with the model group, the norfloxacin group, the low- and high-dose Xueniao capsule groups showed a decreased ratio of the left kidney to the right kidney and organ index(
P
<
0.05,
P
<
0.01), dwindled levels of WBC, NEUT, MONO, and LY(
P
<
0.05,
P
<
0.01), and reduced levels of NF-
κ
B, IL-6, and TNF-
α
(
P
<
0.05,
P
<
0.01). The medium-dose Xueniao capsule group showed a decreased ratio of the left kidney to the right kidney and organ index(
P
<
0.05,
P
<
0.01), reduced levels of WBC, NEUT, MONO, and LY(
P
<
0.05,
P
<
0.01), and dwindled levels of IL-6 and TNF-α(
P
<
0.05,
P
<
0.01). Network pharmacological analysis revealed 17 active compounds from Smilacis Chinae Rhizoma, 18 active compounds from Coicis Semen, six active compounds from Trachycarpi Petiolus, and 39 key genes for the treatment of APN in Xueniao capsule. GO enrichment analysis demonstrated 704 biological processes, 22 cellular components, and 59 molecular functions. Sixty-two pathways were enriched in KEGG enrichment analysis. The experimental verification results showed that compared with the blank group, the model group showed increased mRNA expression of prostaglandin-endoperoxide synthase 2 (PTGS2), mitogen-activated protein kinase 1 (MAPK1)/extracellular signal-regulated protein kinase 2 (ERK2),phosphoinositide 3 kinase (PI3K),protein kinase B2(Akt2),Janus kinase 2 (JAK2),and signal transducer and activator of transcription 3 (STAT3)and protein expression of PI3K, Akt2, JAK2, and STAT3 (
P
<
0.05,
P
<
0.01). Compared with the model group, the low-dose Xueniao capsule group showed decreased mRNA expression of MAPK1, PI3K, JAK2, and STAT3 and protein expression of PI3K, JAK2, and STAT3 (
P
<
0.05,
P
<
0.01). The medium-dose Xueniao capsule group showed decreased mRNA expression of MAPK1, PTGS2, PI3K, JAK2, and STAT3, and protein expression of PI3K, JAK2, and STAT3 (
P
<
0.05,
P
<
0.01). The high-dose Xueniao capsule group showed reduced mRNA expression of PTGS2, MAPK1, PI3K, Akt2, JAK2, and STAT3 and protein expression of PI3K, Akt2, JAK2, and STAT3 (
P
<
0.05,
P
<
0.01).
Conclusion
2
Xueniao capsule has a certain curative effect on APN via multiple targets and multiple pathways. The mechanism may be related to the inhibition of the PI3K/Akt signaling pathway and the JAK2/STAT3 signaling pathway.
LEVIN G , DUFFIN K L , OBUKOWICZ M G , et al . Differential metabolism of dihomo- γ -linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E 1 and prostaglandin E 2 [J]. Endocr J , 2002 , 365 ( 2 ): 489 - 496 .
LUCIDO M J , ORLANDO B J , VECCHIOALEX J , et al . Crystal structure of aspirin-acetylated human cyclooxygenase-2:insight into the formation of products with reversed stereochemistry [J]. Biochem , 2016 , 55 ( 8 ): 1226 - 1238 .
HE C , LIN H Y , WANG C C , et al . Exopolysaccharide from Paecilomyces lilacinus modulates macrophage activities through the TLR4/NF- κ B/MAPK pathway [J]. Mol Med Rep , 2019 , 20 ( 6 ): 4943 - 4952 .
TANAKA T , NARAZAKI M , KISHIMOTO T . IL-6 in inflammation,immunity,and disease [J]. Cold Spring Harb Perspect Biol , 2014 , 6 ( 10 ):a 016295, .
MA X J . Regulation of cytokine gene expression in immunity and diseases regulation of IL-6 in immunity and diseases [J]. Adv Exp Med Biol , 2016 , 5 ( 4 ): 79 - 88 .
LI J , ZHANG H B , HUANG W L , et al . TNF- α inhibitors with anti-oxidative stress activity from natural products [J]. Curr Top Med Chem , 2012 , 12 ( 13 ): 1408 - 1421 .
CHATZANTONI K , MOUZAKI A . Anti-TNF- α antibody therapies in autoimmune diseases [J]. Curr Top Med Chem , 2006 , 6 ( 16 ): 1707 - 1714 .
PUNYTE V , VILKEVICIUTE A , GEDVILAITE GRETA , et al . Association of VEGFA,TIMP-3,and IL-6 gene polymorphisms with predisposition to optic neuritis and optic neuritis with multiple [J]. Sclerosis Ophthalmic Genet , 2020 , 42 ( 1 ): 1 - 10 .
MIZUI M . Natural and modified IL-2 for the treatment of cancer and autoimmune diseases [J]. Clin Immunol , 2018 , 9 ( 206 ): 63 - 70 .
ABBAS A K , TROTTA E R , SIMEONOV D , et al . Revisiting IL-2: biology and therapeutic prospects [J]. Sci Immunol , 2018 , 3 ( 25 ): 1482 .
BANERJEE S , BIEHL A , GADINAX M , et al . JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects [J]. Drugs , 2017 , 77 ( 5 ): 521 - 546 .
GAO Q W , LIANG X W , SHAIKH A S , et al . JAK/STAT signal transduction: promising attractive targets for immune,inflammatory and hematopoietic diseases [J]. Curr Drug Targets , 2018 , 19 ( 5 ): 487 - 500 .
WANG D Z , JINX M Y , ZHAO X Y , et al . FGF1 ΔHBS ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation [J]. Cell Death Dis , 2019 , 10 ( 6 ): 464 .